­­Orphazyme A/SCompany announcement                                                                                       No. 73/2020Inside InformationCompany Registration No. 32266355

See the article here:
Orphazyme provides regulatory update on arimoclomol for NPC

BASEL, Switzerland and NEW YORK, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced a collaboration to develop and commercialize relugolix – a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist – in oncology and women’s health in the U.S. and Canada. Pfizer will also receive an exclusive option to commercialize relugolix in oncology outside the U.S. and Canada, excluding certain Asian countries.

See more here:
Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health

STAMFORD, Conn., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for KORSUVA™ Injection (difelikefalin) for the treatment of moderate-to-severe pruritus in hemodialysis patients. KORSUVA Injection received Breakthrough Therapy Designation from the FDA for this indication. Cara has requested Priority Review for the NDA which, if granted, could result in a six-month review process. The FDA has a 60-day filing review period to determine whether the NDA is complete and acceptable for filing.

See original here:
Cara Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KORSUVA™ Injection in Hemodialysis Patients with...

--Received Gross Proceeds of $110 Million from Previously Announced PIPE Financing----Executed Additional PIPE Financing of $15 Million--EMERYVILLE, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced the closing of the previously announced $110 million private investment in public equity (PIPE) financing, as well as a newly executed PIPE financing for an additional $15 million in gross proceeds resulting from the sale of shares of its common stock at a price per share of $3.71. Gross proceeds from the two PIPE financings total $125 million, before deducting placement agent fees and offering expenses. The PIPE financings are supported by a consortium of high quality new and existing institutional investors with expertise in health care, including Redmile Group, Avidity Partners, EcoR1 Capital, BVF Partners L.P. and Versant Ventures.

Read the original here:
Gritstone Oncology Announces Private Placement Financings Totaling $125 Million

NEW YORK, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Better Choice Company (OTCQB: BTTR) (“Better Choice”), an animal health and wellness company, has qualified to trade on the OTCQX® Best Market. Better Choice Company Inc. upgraded to OTCQX from the OTCQB® Venture Market.

Link:
Better Choice to Begin Trading on the OTCQX

SAN CARLOS, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that Maria Fardis, PhD, MBA, President and Chief Executive Officer of Iovance, plans to present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021, at 10:50 a.m. ET. The live and archived webcasts of the presentation and breakout session will be available in the Investors section of the Iovance website at http://ir.iovance.com.

Originally posted here:
Iovance Biotherapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021

NEW YORK, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that it has entered into a definitive agreement to sell its Priority Review Voucher (“PRV”) to United Therapeutics Corporation (Nasdaq: UTHR), based on an agreed valuation of $105 million.

See more here:
Y-mAbs Announces Sale of Priority Review Voucher

BOSTON, Dec. 28, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced results of the primary data cut from its Phase 3 clinical trial evaluating the safety and efficacy of eprenetapopt with azacitidine (AZA) versus AZA alone in TP53 mutant myelodysplastic syndromes (MDS). The trial did not meet the predefined primary endpoint of complete remission (CR) rate.   Analysis of the primary endpoint at this data cut demonstrated a higher CR rate in the experimental arm receiving eprenetapopt with AZA versus the control arm receiving AZA alone, but did not reach statistical significance. In the intention-to-treat population of 154 patients, the CR rate in the eprenetapopt with AZA arm was 33.3% (95% CI: 23.1% - 44.9%) compared to 22.4% (95% CI: 13.6% - 33.4%) in the AZA alone arm (P = 0.13).

See more here:
Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS)

HOUSTON, Dec. 28, 2020 (GLOBE NEWSWIRE) -- via InvestorWire – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announces that it has been featured in a broadcast via NetworkNewsAudio (NNA), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio press release covers CNS Pharmaceuticals’ recent announcement that the Investigational New Drug (IND) application for its lead product candidate, Berubicin, for the treatment of Glioblastoma Multiforme (GBM) is now approved and in effect as filed with the US Food and Drug Administration (FDA).

See the original post:
CNS Pharmaceuticals Featured in Syndicated Broadcast Covering Recent FDA Approval of IND Application

Read more:
FitTrack Scale Reviews – Best BMI Smart Scale? – Procut Review by Mike Vaughn

GAITHERSBURG, Md., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced initiation of PREVENT-19, its pivotal Phase 3 study in the United States and Mexico to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373, the Company’s COVID-19 vaccine candidate. The trial builds on research from Phase 1/2 studies demonstrating that the vaccine provoked a robust immune response, generated highly neutralizing antibodies against the virus and was generally well-tolerated.

Go here to read the rest:
Novavax Announces Initiation of PREVENT-19 Pivotal Phase 3 Efficacy Trial of COVID-19 Vaccine in the United States and Mexico

– Company plans to complete rolling submission in the first half of 2021 –

Read more:
Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

View post:
Sanofi: Information concerning the total number of voting rights and shares - November 2020

These Product Offerings Include CBD Infused: Face Moisturizer, Anti-Wrinkle Cream, Collagen/Tightening/Detoxifying Face Masks, Lip Balm, Hand & Foot Cream, Transdermal Patch, Massage & Body Oil, Body Spray, and Roll-On Product

Read more:
Tauriga Sciences Inc. Expands its CBD Infused Skin Care Offerings to Include More Than 10 Different Products

Pompano Beach, Fl, Dec. 24, 2020 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) ("BioStem" or the "Company"), a leading life sciences company specializing in perinatal tissue allografts for use in regenerative therapies, today announced that it has filed its quarterly reports for 2020 to become current with OTC Markets.

Read more here:
BioStem Technologies, Announces Filing of 2020 Quarterly Reports

HALIFAX, Nova Scotia, Dec. 24, 2020 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended October 31, 2020.

See the original post:
MedMira Reports First Quarter Results FY2021

See more here:
Reversirol Reviews – Best Diabetes Supplement launched? - Product Review by Mike Vaughn

VANCOUVER, British Columbia, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Lui Franciosi is proud to announce the launch of his new YouTube channel. As a pharmacologist and former executive in the pharmaceutical industry, Dr. Franciosi’s videos will focus on topics related to health and pharma care, as well as topics related to entrepreneurship, seniors care and COVID-19.

See the original post:
Lui Franciosi of Franciosi Consulting Launches YouTube Channel

Will Trade on the Nasdaq Global Market Under Ticker “GBS” Will Trade on the Nasdaq Global Market Under Ticker “GBS”

Read more:
GBS Inc. Announces Pricing of Initial Public Offering

Annual Meeting to be adjourned solely with respect to Item 2, and Item 2 to be modified to decrease the proposed aggregate number of shares of common stock that the Company would be authorized to issue from 500,000,000 shares to 400,000,000 shares Annual Meeting to be adjourned solely with respect to Item 2, and Item 2 to be modified to decrease the proposed aggregate number of shares of common stock that the Company would be authorized to issue from 500,000,000 shares to 400,000,000 shares

Read more here:
Ocugen Inc. Announces Plan to Adjourn Annual Meeting of Stockholders, Modify Proposal Regarding Increase in Number of Authorized Shares